Literature DB >> 10691100

Platelet activation during angiotensin II infusion in healthy volunteers.

P T Larsson1, J H Schwieler, N H Wallén.   

Abstract

The present study was undertaken to evaluate the effects of an intravenous infusion of angiotensin II (10 ng/kg per min) on platelet function and coagulation in vivo in 18 healthy males. The infusion increased mean arterial pressure by 23+/-2 mm Hg. Plasma beta-thromboglobulin levels, reflecting platelet secretion, increased by 66+/-24% during the infusion, as did also platelet surface expression of P-selectin as measured by flow cytometry. Platelet fibrinogen binding increased, whereas platelet aggregability, assessed by ex vivo filtragometry, was unaltered. Angiotensin II caused mild activation of the coagulation cascade with increases in plasma levels of thrombin-antithrombin complex and prothrombin fragment F1 + 2. In conclusion, angiotensin II has mild platelet-activating effects in vivo and also enhances coagulation. Markers of platelet secretion are significantly increased, whereas markers of platelet aggregability are less affected. The clinical relevance of these findings remains to be clarified.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10691100

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  15 in total

1.  Mechanisms underlying the cerebral microvascular responses to angiotensin II-induced hypertension.

Authors:  Shantel A Vital; Satoshi Terao; Mutsumi Nagai; D Neil Granger
Journal:  Microcirculation       Date:  2010-11       Impact factor: 2.628

2.  Does the mean platelet volume have any importance in patients with acute pulmonary embolism?

Authors:  Ermis Hilal; Yucel Neslihan; Gulbas Gazi; Turkkan Sinan; Aytemur Zeynep Ayfer
Journal:  Wien Klin Wochenschr       Date:  2013-06-27       Impact factor: 1.704

Review 3.  Pharmacological interventions into the renin-angiotensin system with ACE inhibitors and angiotensin II receptor antagonists: effects beyond blood pressure lowering.

Authors:  Rainer Düsing
Journal:  Ther Adv Cardiovasc Dis       Date:  2016-04-27

Review 4.  A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme.

Authors:  Kenneth E Bernstein; Frank S Ong; Wendell-Lamar B Blackwell; Kandarp H Shah; Jorge F Giani; Romer A Gonzalez-Villalobos; Xiao Z Shen; Sebastien Fuchs; Rhian M Touyz
Journal:  Pharmacol Rev       Date:  2012-12-20       Impact factor: 25.468

5.  Roles of Coagulation and fibrinolysis in angiotensin II-enhanced microvascular thrombosis.

Authors:  Elena Y Senchenkova; Janice Russell; Charles T Esmon; D Neil Granger
Journal:  Microcirculation       Date:  2014-07       Impact factor: 2.628

6.  Inhibition of platelet activation by clopidogrel prevents hypertension-induced cardiac inflammation and fibrosis.

Authors:  Li-Xin Jia; Guan-Ming Qi; Ou Liu; Tao-Tao Li; Min Yang; Wei Cui; Wen-Mei Zhang; Yong-Fen Qi; Jie Du
Journal:  Cardiovasc Drugs Ther       Date:  2013-12       Impact factor: 3.727

7.  Angiotensin II upregulates endothelial lipase expression via the NF-kappa B and MAPK signaling pathways.

Authors:  Xiaoli Zhang; Minghui Wu; Hong Jiang; Jing Hao; Qingli Zhang; Qing Zhu; Gaowa Saren; Yun Zhang; Xiaohui Meng; Xin Yue
Journal:  PLoS One       Date:  2014-09-24       Impact factor: 3.240

8.  Platelets and renal failure in the SARS-CoV-2 syndrome.

Authors:  Muhanad Taha; Dahlia Sano; Samer Hanoudi; Zahia Esber; Morvarid Elahi; Ali Gabali; Teena Chopra; Sorin Draghici; Lobelia Samavati
Journal:  Platelets       Date:  2020-09-06       Impact factor: 3.862

Review 9.  The Impact of the Renin-Angiotensin-Aldosterone System on Inflammation, Coagulation, and Atherothrombotic Complications, and to Aggravated COVID-19.

Authors:  M Ekholm; T Kahan
Journal:  Front Pharmacol       Date:  2021-06-17       Impact factor: 5.810

Review 10.  Thromboplasminflammation in COVID-19 Coagulopathy: Three Viewpoints for Diagnostic and Therapeutic Strategies.

Authors:  Satoshi Gando; Takeshi Wada
Journal:  Front Immunol       Date:  2021-06-11       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.